Replay available

Nordhealth AS (Oslo:NORDH) Q3 2026 Earnings Call

Nordhealth AS (Oslo:NORDH) reported Q3 2026 results on this call. Replay available.

Tue, November 10, 2026 at 7:00 AMendedReplay
Nordhealth AS (Oslo:NORDH) Q3 2026 Earnings Call
Company
Nordhealth AS (OSL:NORDH)
Period
Q3 2026 earnings call
Date
Tue, Nov 10, 2026, 7:00 AM ET
Replay
Watch the replay on this page · 37 min

On 6ix: 6ix.com/event/nordhealth-as-nrdhf-q3-2026-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Great. Hi, everyone. And welcome to the Q3 2026 presentation. I hope you can all see the screen. Today's presenters are myself, Charles Mubain. I'm the CEO of NordHealth. And I'm joined by my colleague, Alex Cram, our CFO. The agenda, as in previous quarters, will be first to go through a company update. Then we'll do a deep dive on the veterinary and Subsequently, the therapy update. And then Alex will go through the financial results and guidance. And we'll leave time at the end for any Q&A. Starting with the company update.

0:46 Just a reminder of our objectives for 2026. One, we want to build the world-leading AI PMS across both therapy and veterinary. And there's a huge opportunity in this platform shift. The second is we wanted to rather reduce the time it takes to go from sign to onboarding, especially for enterprise on the veterinary side. So productize that onboarding motion. The third is localizing ProVet for Germany, initially targeting German small animal. The fourth is to complete the majority of the migration of customers to the unified platform.

1:34 And the last is to do this while not having a significant increase in our costs in order to improve profitability. Now looking at our growth, we've been growing at a 43% CAGR since present management took over. And we reached a signed AR of 53.1 million at the end of Q3 2026. These are reporting in constant currency. If we look now at implemented AR, year over year, we've grown 13.5%. Our net retention has been around 109%.

2:26 primarily driven by ProVet expansion of enterprise customers. And our churn rate remains very low at 3.2%. You can also see that we've got a significant amount of customers, 3.3 million euros worth, which are signed but not yet implemented. So our implementation backlog is quite significant as well. Now, doing a deep dive on veterinary, on the missions that we highlighted, the first mission is to continue the expansion in the US, UK, and Germany. We signed almost 400,000 euros of new AR in Q3.

3:12 We've also brought on a new VP of marketing in Mo Packer, which has already had a huge impact on improving the marketing functionality. And we look forward to seeing the improvements he makes going forward. We reached a significant milestone in that we've got over 100 Vet for Pets clinics live at the end of Q3, which is an implementation which has been going on for quite a few years. So this is a significant milestone for us. And in total, the second milestone was that we've got over 3,000 clinics live on ProVets, which is a nice milestone on the veterinary business. The second mission is building and leading AI PMS. There's a huge amount of opportunity with this new technology.

4:02 So the first is a new, we built a new, faster, simpler consultation page with an AI scribe embedded that we've been rolling out to most of our customers. This is one of the primary surfaces that they work on. And so that was a big change for our customers. The second is we launched an MCP, which basically enables you to connect all the Provid data with any LLM of your choice, like ChatGPT or Cloud and so on. And that's been hugely popular with the initial users of it. Clinics are using it for auditing their numbers, for reporting, for testing pricing changes, and so on. And lastly, but not least, we're also continuing the investment in our AI scribe and have grown the number of users that we've got in our AI scribe quite significantly.

4:55 On the third mission is reduce time to value. We've launched an onboarding wizard to try to productize the onboarding motion. now in the UK, US and Germany, this basically shifts it from being a human led onboarding to self service customer inputs. And we take a much more opinionated view of how an account should be set up to be able to automate the load that work. And historically, from signing to go live could take over 12 weeks. Now it's you can be done in around one week. So the significant improvements by prioritizing the onboarding function. Looking at the growth year over year, veterinary grew 14.4%.

5:43 Our net retention was 111%. And churn remains extremely low at 2.6%. Now, looking at our profitability, we've been able to more than double our profitability year to date Q3 2026 versus 2025 with a certain period of time. from 0.5 to 1.3 million in adjusted EBITDA minus capex, which is a rough proxy for cash flow for us. This 0.8 million change was driven by our gross profit as we grow. We've unlocked 0.7 million in additional gross profits. We have reinvested some of that into product development, 0.4 of that. Um, and professional services to be able to, uh, uh, roll out these larger corporates.

6:46 Uh, we have, however, made a savings on sales and marketing, um, and also a 0.6 and GNA has also improved by 0.6 million. The next is how we've been growing over the years, right? We show this graph every quarter, but the UK is a large driver of our growth in year-to-date 2026, as well as Southern Europe. And we've also been growing in the Nordics as well. As we can see though, the DAC market is only 3.1 now. So we see a huge opportunity to be able to expand into the region.

7:36 Now looking at the breakdown of our growth, we can see that enterprise continues to be a significant driver of growth as there's a great product market fit in ProVet for enterprise. And a lot of our enterprise customers are also growing thereby. and once they acquire new Aquileinics, they normally migrate them over to ProVet. You can also see that our payments and partners revenue has increased as we've been upsetting ProVet Pay, our new AI scribe, and soon we'll be launching conversations, which is a two way SMS and seeing WhatsApp platform. despite the fact that enterprise is a significant percentage of revenue making up over 56% of our AR growth, only our top three customers only make up 18% of our AR.

8:38 Now, We completed the migration of Vetserv and ProVetWin in 2024, ProVetNet in 2025, and Sanamales in 2026. So we can see the share of AR on ProVets is over 90% now, which is an increase from 43% in 2022. So we've had a successful track record of migrating these customers that we've acquired. We're currently working on finalizing the VetVision migration in Denmark, which we expect to be done this year. And the big next new migration will be in the DACH region, where we've started migrating in Germany for small animal.

9:27 Now, deep diving on the therapy business units. We've got three missions. Number one, similar to veterinary, is build a leading AI PNS to make sure we are winners and not laggards in this new platform shift. In Q3 alone, we were able to deliver over 100,000 hours of transcription and over 200,000 AI-generated notes to our customers. We have also done a lot of improvements in our AI Scribe, such as AI personalized templates that you can create for the AI Scribe, as well as an AI engine upgrade. So we've improved the speed and quality of our AI Scribe. On the Aspect migration, we have 1,642 users migrated at the end of Q3, up from 1,000 at the end of Q2.

10:21 we're seeing an accelerating pace of migration and as we release new functionality, additional cohorts and larger cohorts are being unlocked to enable our migrations. We've been investing a huge amount into improving the performance and UX improvements as we hear feedback from different cohorts.

10:45 The third is on the growth side.

10:46 We signed over 300,000 of new AR in Q3 and over 1.5 million in year to date 2026. This is both new business nuts, which is 19% more than we've had in year to date 2025. So we've actually been able to continue to increase our growth rate. The second is AI continues to be a key driver of growth. We can see from the usage that they've done a great job actually building a market leading AI scribe, which is getting market share in the Nordics. Also, retention has also improved across the portfolio as we're targeting the right ICP customers, therapists and allied health professionals. And second, that we've got better product market fits.

11:47 Therapy has grown 12% year over year, 12.1%. Net retention was 106% and that was mostly driven by the ascribe upsell churn has reduced to 4.2%. So we're very happy about that. We ended the quarter at 18.1 million euros of AR. Profitability has also improved year-to-date, ending Q3 2026 relative to 2025, the same period. The drivers of profitability are that gross profits, which is as we grow, that unlocks additional gross profits and we become more efficient on the COGS side. we've been able to add 1.1 million of additional profitability from that. But we've also reinvested some of those processes into sales and marketing to be able to sustain that growth and upsell our products and also sell the migrations to our customer base.

12:50 Now, we can also see that in Q3, 2026, the majority of our revenue is coming from cloud and that's a growing share where today 61% of our revenues on our cloud products. You will see this number similar to what we did in veterinary get larger and larger. assuming we don't acquire any net new products at the meantime, which would increase that dark place, I would love to acquire new modern cloud software is an attractive price, but I haven't found many of those of late. So most likely in the acquisition will be at the non cloud side.

13:35 Now hand over to Alex for financial results.

13:41 Thanks a lot, Charles. And hello, everyone. So starting with reported revenue in Q3 2026, we did 15.2 million of revenue, which is 17.5% increase versus the same quarter last year. More importantly, our underlying recurring revenue growth was 17%, going from 11.5 million in Q3 2025 to 13.5 million in Q3 2026. It's worth highlighting that this is an increase in the growth rate compared to Q2 2026 year on year growth, which was 14.6%. The large enterprise rollouts have progressed a lot in Q3, which has added meaningfully to recurring revenue.

14:27 At the same time, other revenues are 1.7 million, which is also higher in Q3 this year than last year due to the pilots, co-developments, and early implementation of newly signed clients. The Q3 2026 share of recurring revenue is 88.6%, very slightly down from 89% in Q3 2025. Now looking year-to-date, the acceleration in year-on-year recurring revenue growth in Q3 has lifted up the overall year-to-date growth rate. For year-to-date 2026, we did 38.7 million of recurring revenue, which is a 14.3% increase versus Q3 year-to-date last year. Total revenue for Q3 year to date has grown 11.9% year on year from 38.3 million to 42.8 million. And the Q3 year to date share of recurring revenue is 90.3% up from 88.4% in Q3 year to date 2025.

15:33 Turning now to adjusted EBITDA minus capex. So as we've been promising all year, we've been controlling costs and allowing revenue growth to translate into improving adjusted EBITDA minus capex. So in Q3, 2026, we had 1.3 million of positive adjusted EBITDA minus capex, which is 1.5 million increase versus Q3, 2025. In addition to the increased gross profit, we've been spending less on product development and G&A to drive this improved adjusted EBITDA minus capex. Q3 is always a good month due to accounting adjustments related to holiday accrual releases over the summer. But overall, the trend and the year-on-year improvement is clearly positive.

16:24 Looking at year to date adjusted EBITDA minus capex. So as you can see the Q3 improvements have improved our year to date position versus Q3 2025. Adjusted EBITDA minus capex for the year now is at minus negative 0.9 million up from negative 2 million year to date 2025. So overall, to achieve that, we've achieved an extra 1.7 million of gross profit from growth, while only adding 0.6 million of fixed costs. now on to the adjusted cash flow. The picture here matches the adjusted EBITDA minus capex trajectory. Q3 year to date adjusted cash flow is negative 0.7 million, which is a 0.9 million improvement versus Q3 year to date 2025. This is closely related to the EBITDA minus capex improvement, which is 1.1 million with the remaining 0.2 million difference due to working capital timing.

17:28 Finally, looking at the September 2026 balance sheet, cash at September is 11.6 million. There were no changes to Goodwill in Q3, no external financing, except for amortization and FX changes. There was no external financing taken in Q3. There were no material equity transactions in Q3 either. As always, the full detailed financial statements for Q3, the P&L balance sheet and cash flow are in the appendices to the report. Now on to guidance. So I'm very pleased to say that we expect to perform quite well against the 2026 guidance that we presented at the beginning of the year. For recurring revenue, we gave a guidance of between 50 million and 53 million, excluding acquisitions for the full year.

18:30 Our year-to-date Q3 actual is $38.7 million, which if we have identical revenue in Q4 than we did in Q3 would mean a full-year recurring revenue of $52.2 million. We do expect to track towards the top end of the guidance range for full-year 2026 recurring revenue. For adjusted EBITDA minus capex, we gave a guidance of between negative 4 million and negative 1 million, excluding acquisitions. Our Q3 year-to-date actual adjusted EBITDA minus capex is negative 0.9 million, which is slightly ahead of the top end of the full-year guidance range. And so we expect to track towards the end towards the top end of or potentially even slightly over perform the guidance range for full year 2026 adjusted EBITDA minus capex.

19:25 We'll present the full year 2026 figures at our Q4 results call on the 2nd of March. And on that call, we will also present the guidance for 2027. Lastly, on the financial calendar, as I mentioned, the Q4 results will be presented on the 2nd of March. One note is that we're currently undertaking an accounting standards conversion from Norwegian GAP, which is what we report under currently, to IFRS. So for full year 2026, we plan to release our results in both NGAP and IFRS. And then from 2027 onwards, we'll present results in IFRS only. and then the full 2027 financial calendar will be published on the website before the 31st of December, 2026.

20:15 I will now turn back over to Charles for Q&A.

20:19 Great. Thanks very much, Alex. So for Q&A, we've got a little functionality where you can just type your questions or so you can just add them there and I can ask them live. What I'll do is I will read the question and then answer the question there. But please feel free to add your Q&A questions in the chat. So question from Guest Guest, which is on the VETBU, which with the vast majority of growth in 2026 having happened in H1, in only 400K of net new AR in Q3, what needs to happen from a commercial perspective in order to achieve the 2026 organic growth goals?

21:10 I'm trying to figure out where the 400K is coming from. If we look through the signing in Q3, most of the signings were in AR, what we look at is on the SME side, we only discuss as well enterprise signings when we've got over 50 locations. So that probably is one of the things that has to do with the timing of it. we're very happy with the amount of enterprise that we've signed in 2026. And on the SME side, we could do much better.

21:55 That's why we brought a new head of marketing and soon hopefully a new head of sales at SME and mid-market sales to focus on that on the veterinary side. I think we've got a huge opportunity. Most of our current demand is actually inbound, and we're looking to shift a lot more towards outbound demand. The second on that is that veterinary had a lead in terms of, sorry, therapy had a lead in terms of getting the AI scribe up and running. Veterinary was a bit slower off the starting block. Since I took over in January, we've changed our trajectory. But we've got a significant opportunity to be able to upsell AI Scribe, similar to what we've done with ProVet Pay. And soon we'll do with conversation as well.

22:46 So between going for outbound on the SME side. Secondly, having additional products that we can upsell and having a dedicated team and customer success to handle that upsell. And third, continuing to sign up more enterprises, I think those should be three main growth drivers. The second question was veterinary growth is mostly driven by existing enterprise rollouts. What is the outlook of the new customer wins? from Matthew Baba. So on the new customer wins, as I mentioned before, we only announced new customer wins once 50 location has been crossed. So as we cross 50 locations with current enterprise and pilots, we will show that growth.

23:41 Um, the next is, um, and yes, enterprise is a big percentage of our growth and we foresee it to be a big percentage of our growth going forward as we've got great product market fit on the vet side for enterprise. And we want to double down on that. we will see growth as well from upsells as well. This mean that new we could do a lot better than we do today in terms of upsell in terms of net new. But I still think that the enterprise will be the biggest driver of growth. Another question from Matthew. Growth is gaining speed in therapy. Can you be more specific on the reasons for this acceleration? And do you have more visibility on the calendar for the end of the migration?

24:29 So on the we're very happy with the performance of growth for therapy, given that they're focusing most of their time on migration. The main drivers of it has been the upsell of the scribe and second, a much lower churn. Right. So those two are the primary factors have been leading to the acceleration therapy growth. Next question. When do you expect ProVet to be fully localized? Oops, sorry. I missed one thing about the end of the migration, right? So the approach for that is we're targeting to have the majority of customers migrated by the end of the year, but it will still continue on to next year. We don't have a specific time as the approach that we take.

25:15 We want to make sure that each cohort that we are localized for is really happy with the product. And we only go to the next cohorts when we've actually got good sentiment in the market with that cohort to make sure we don't get high churn from the migration. And so it's always tough to figure out when someone will be satisfied with a certain thing, right? a competitor to gain market share in Norway. The next is what do you expect profit to be for like last for Germany? Um and what do you plan to migrate and do you plan to migrate Vetra customers to ProVet?

26:09 So one is for German Small Animal, we do have initial customers on ProVet. We're still iterating with those customers to make sure there is great product market fit, but they are using ProVet every day. Today, which is great. Some of these customers are very happy. Um, but we still have some gaps that we should fill. We need to fill in terms of integration.

26:31 So on to make sure that we can push the migration forward more aggressively.

26:37 Yes, our plan is to migrate all Vetra customers to ProVets. We actually don't name ProVets in the DACH region as Vetra and the legacy platform is called Vetra Classic. So it will be a name that the DACH consumer knows quite well. another question on AI scribe and clinical assistance from startups like tandem health are developing quickly. How do your therapy solutions compare to these new peers, particularly on the technical side? That's a great question. The AI scribes all are basically wrappers around a speech-to-text model, whether they use 11Labs or OpenAI or Speechmatics.

27:27 They're third parties that we use to capture speech. Then we train those models with a certain vocabulary, and then those create notes. So that is the basic. All of these are wrappers. We all use the same tool. So we can all have the same value. That being said, we do have a right to win in that we control the platform through which it happens. And so we can provide a way better UX. So we compete against Tandem and otherwise on the UX. So either A, you force the user to go somewhere else. And then notes are added back and you have to press add another click to be able to approve those notes. Or B is you can do it all within one software.

28:15 We've had good success competing against them because the fact that if you don't have a a scribe of high quality, people usually use third party. But for us, we've had our scribe has been quite high quality. And so as a result, we've been able to compete quite well. On the vet side, though, there is an additional moat that the scribe not only adds text, but also adds billable items. And so that's something that we're uniquely positioned to do because we do have the list of items and the pricing and so on. We also add vitals automatically and diagnoses. So that's something where they can't really compete on that side because they can't be able to add these items into the medical record.

29:02 Next question is adjustments to EBITDA have increased this year. What are these one-off costs and should we expect more in the coming quarters? So maybe Alex.

29:14 Yeah, happy to take this one. So there's two primary buckets to the EBITDA adjustments. One is the PSOP, which is the share option scheme we have for executives, which is non-cash and non-defined at this stage, it's based on company future performance. And so we think it distorts the EBIT data to include in there. So we strip out the PSOP charges. That was about a million dollars. year to date. And then the rest of it is primarily restructuring costs. So you'll have seen we've reduced headcount somewhat through the year. And in general, I mean, 2026 has probably been one of the most transformational years in Nord Health's history. We've invested a lot in Putting the right people in in the right seats.

30:18 This is not an exercise we want to do every year and so we for sure do not expect the same level of Non-recurring items and EBITDA adjustments to continue into into future years We do also see at the end of a migration Normally, we don't need to migrate

30:42 Uh anymore and so that causes a one off restructuring. So you should see that as we end in certain migration, you will see one off restructuring there. The next one is from Guillaume Prisch. Enterprise is now close to half your vet AR. Where does the next leg come from? UK groups, US or Germany? If we think about our enterprise will continue to be a big part of our strategy. we've got great product market fit and I think we've got a really good product for enterprise and the gap between us and the next person is also increasing as we make great investments to make their experience even better. An example of that is we've got a whole new reporting platform that connects via MCP, which has been hugely popular for enterprise groups.

31:31 the speed at which that data processing, we built the whole reporting from scratch to make sure that it works really well for enterprise at scale. We can have hundreds of different groups, locations on the same environments. And so we do see, as you pointed out your question, that the next leg will come from additional UK groups. U.S. and Germany. Those are the main enterprise target markets for us. I'm also focusing more of my time on it. So we've got someone dedicated for SME at mid-market sales that we're looking to onboard. And I'm focusing most of my time on the vet side, finding our new groups and making sure our current groups are happy and use the full functionality of ProVet.

32:23 Next one from Rodolfo. Adjustments to EBITDA were 0.9 million in Q3 2026 and 3.5 million year-to-date, of which only about 1 million is PSOP. Could you break down the remaining one-time items and tell us whether you expect them to continue to 2027? Alex.

32:46 Yeah, this is I think exactly the same question that was asked before. So I think the answer will have probably satisfied it. And Rodolfo, you've correctly given the breakdown that I gave. If you do have a follow up question to it, feel free to ask it in the Q&A. But I think this question has been answered. Looks like the next one is also on financials. So gross profit margin fell to 76% from 81% a year ago. What is driving this and where do you expect it to settle once the cloud migration is complete? So thanks for the question, Rodolfo.

33:31 On the gross margin, there's two primary items that have caused the increase. One is essentially running dual cogs for two platforms while we migrate on the therapy side. So we still have costs on the Aspit desktop platform, legacy ones. And we have the increasing costs on the new unified platform. And we have a service team that is that is supporting both platforms and supporting the transition between both platforms. So there's definitely a cost up on the migration side. And then on the vet side, as Charles has been mentioning, we've added all of these additional features and functionalities.

34:20 particularly around the MCP and the data reporting and the ability to query the data. This is something that we don't yet charge fully separately for. We want to drive adoption. It has in the short term increased, increased the amount of infrastructure and as a result, the cogs. But we do expect into the future that as we have more users on the platform, the cogs there won't scale with the upfront investments we've had to make. And so we do, we're not going to guide an exact figure of where the gross margin is going to go, but we do see it improving again.

34:56 Thanks, Alex. A question from Guillaume. When an Aspect user migrates to a unified platform, does it change what they pay at migration and over the following year through price and AI scribe? And so is the migration AR neutral or creative? That's a great question. So we've done a few of these migrations. We've learned a couple of different lessons. One lesson is that at the time of migration, when you are sensitive, do not change their price because that will create the delay in the migration. So what we've done normally is we've increased the price of the legacy platform, in this case Aspets, to match somewhat the price for that same plan that they would pay on the new platform. then we migrate them without having to have the competition around price. It's the same price from our side.

35:46 We've got big cost savings, though, because we don't have to pay for Citrix licenses. We don't have to pay for Microsoft licenses for those customers. And then the second, the way that we do get an increase in revenue per customer per user once they migrate is that the AI scribe is available for them in a much more seamless way versus being a separate experience as it is when you're handling a server-based product. And so we can actually increase the amount of people attachment rates that we've got for a scribe. And as we launch new, more and more new products, we'll be able to upsell those as well.

36:33 And the chance that the attachment rate is higher on that. So yes, it should be a creative on the revenue side, but also much more creative on the margin side too. Great. Any other questions?

37:03 Perfect. Well, thank you very much, everyone, for your time and your questions. And we will see you again for our Q4 reporting in March. Thank you very much. Thanks a lot, everyone.

Follow Nordhealth AS into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Charles Mubain

CEO of NordHealth

Alex Cram

CFO of NordHealth

More from Nordhealth AS